Daniel Jamieson awarded The Princess Royal Silver Medal

To unlock the true potential of Artificial Intelligence, pharma companies must adopt a robust data strategy, generating and harmonising data specifically for AI applications

This blog post delves into the specific challenges posed by the complexities of interpreting biomedical language with a focus on Named Entity Recognition (NER), setting the stage for a deeper exploration of how Artificial Intelligence (AI) can help.

Manual curation and traditional NLP have limitations holding back our ability to fully leverage available data for drug development decision-making – this post dives into the promise of LLMs to overcome these limitations.